A multicenter, double-blind, randomized, active controlled, parallel group trial comparing the combinations of valsartan 80 mg plus hydrochlorothiazide 12.5 mg to valsartan 80 mg in patients with mild to moderate essential hypertension not adequately controlled with valsartan 80 mg.
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Valsartan/hydrochlorothiazide (Primary) ; Valsartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Nov 2011 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.
- 07 Nov 2011 Actual end date (Jun 2006) added as reported by ClinicalTrials.gov.
- 14 Nov 2005 New trial record.